Testicular Cancer Tumor Markers and Their Role in Diagnosis and Treatment. Medically reviewed by Darragh O'Carroll, MD — Written by Daniel Yetman on May 1, 2023. Tumor markers; ...

March 27, 2008 — Within the Surveillance, Epidemiology, and End Results (SEER) registry, there is substantial variation in tumor-marker reporting for testis cancer, according to an analysis ...

A standard part of testicular cancer care isn't used in more than half of all patients who have the condition, researchers have found. The tumor markers can show presence or absence of disease.

Tumor markers such as Alpha Feto Protein (AFP) and Human Chorio Gonadotropin (HCG) help in the diagnosis and prognosis of testicular cancer.

Cancer has spread outside of the testicle and into neighboring tissue; cancer has not spread to any lymph nodes or distant parts of the body; tumor marker levels are still within standard ranges 1S ...

Pant-Purohit, M, Brames, M, Abonour, R, et al. Tumor marker rise during second course high dose chemotherapy in recurrent testicular cancer: outcome analysis. J Bone Marrow Res 2013;1:118-118 Crossref ...

Tumors are heterogenous masses of cells that rapidly divide. Many cells have different mutations, functions, and ways to ...

Serum tumor markers play a more critical role in testicular germ cell tumor management than in any other solid organ malignancy. Here, Barlow and colleagues discuss how the serum levels of AFP ...

Tumor markers for testicular cancer include lactate dehydrogenase (LDH), alpha-fetoprotein (AFP), and human chorionic gonadotropin (hCG). Stage 0 testicular cancer.

More genetic markers for inherited testicular cancer identified. ScienceDaily . Retrieved June 2, 2025 from www.sciencedaily.com / releases / 2021 / 07 / 210729083424.htm ...

Serum-based tumor markers, which are one indicator of the presence of cancer cells, are helpful in several aspects of the care of patients with testis cancer, including diagnosis, prognostication ...

A standard part of testicular cancer care isn’t used in more than half of all patients who have the condition, researchers at the University of Michigan Comprehensive Cancer Center have found.